| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | |
Filed by the Registrant ☑ | | | Filed by a Party other than the Registrant ☐ |
Check the appropriate box: | |||
☐ | | | Preliminary Proxy Statement |
☐ | | | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
☑ | | | Definitive Proxy Statement |
☐ | | | Definitive Additional Materials |
☐ | | | Soliciting Material under §240.14a-12 |
Proto Labs, Inc. |
(Name of Registrant as Specified In Its Charter) |
(Name of Person(s) Filing Proxy Statement if other than the Registrant) |
Payment of Filing Fee (Check the appropriate box): | ||||||
☑ | | | No fee required. | |||
☐ | | | Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. | |||
| | (1) | | | Title of each Class of securities to which transaction applies: | |
| | |||||
| | (2) | | | Aggregate number of securities to which transaction applies: | |
| | |||||
| | (3) | | | Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): | |
| | |||||
| | (4) | | | Proposed maximum aggregate value of transaction: | |
| | |||||
| | (5) | | | Total fee paid: | |
| | | | |||
☐ | | | Fee paid previously with preliminary materials. | |||
| | | | |||
☐ | | | Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing. | |||
| | | | |||
| | (1) | | | Amount previously paid: | |
| | |||||
| | (2) | | | Form, Schedule or Registration Statement No.: | |
| | |||||
| | (3) | | | Filing Party: | |
| | |||||
| | (4) | | | Date Filed: | |
| |
| Proto Labs, Inc. will hold its 2021 Annual Meeting of Shareholders online via live webcast on Tuesday, May 18, 2021 at http://www.virtualshareholdermeeting.com/PRLB21. The Annual Meeting will begin at 8:30 a.m. Central Time. The proxy materials were made available to you via the Internet or mailed to you beginning on or about April 6, 2021. | | ||||||
| TIME AND DATE: | | | 8:30 a.m. Central Time, on Tuesday, May 18, 2021 | | |||
| ITEM OF BUSINESS: | | | At the Annual Meeting, our shareholders will: | | |||
| | | 1. | | | Elect eight directors to hold office until the next Annual Meeting of Shareholders or until their successors are duly elected. | | |
| | | | | | |||
| | | 2. | | | Vote on the ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for fiscal 2021. | | |
| | | | | | |||
| | | 3. | | | Vote on an advisory basis to approve the compensation of the officers disclosed in the accompanying Proxy Statement, which we refer to as a “say-on-pay” vote. | | |
| | | | | | |||
| | | 4. | | | Act on any other matters that may properly come before the Annual Meeting, or any adjournment or postponement thereof. | | |
| RECOMMENDATION: | | | The board of directors recommends that shareholders vote FOR each of the following: | | |||
| | | | | | |||
| | | 1. | | | The director nominees named in the accompanying Proxy Statement. | | |
| | | | | | |||
| | | 2. | | | The ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for fiscal 2021. | | |
| | | | | | |||
| | | 3. | | | The approval of the say-on-pay proposal. | | |
| Only shareholders of record at the close of business on March 23, 2021 may vote at the Annual Meeting or any adjournment or postponement thereof. | | ||||||
| | | | | By Order of the Board of Directors | | ||
| | | | | ![]() | | ||
| | | | | Jason Frankman Secretary | |
| PROXY SUMMARY | |
| Name | | | Age | | | Director Since | | | Independent | | | Audit Committee | | | Compensation Committee | | | Nominating and Governance Committee | |
| Robert Bodor | | | 48 | | | 2021 | | | No | | | | | | | | |||
| Archie C. Black | | | 59 | | | 2016 | | | Yes | | | | | | ![]() | | | | |
| Sujeet Chand | | | 63 | | | 2017 | | | Yes | | | | | | | | ![]() | | |
| Moonhie Chin | | | 63 | | | 2019 | | | Yes | | | | | | | | ![]() | | |
| Rainer Gawlick | | | 53 | | | 2008 | | | Yes | | | ![]() | | | ![]() | | | | |
| John B. Goodman | | | 61 | | | 2001 | | | Yes | | | ![]() | | | ![]() | | | | |
| Donald G. Krantz | | | 66 | | | 2017 | | | Yes | | | | | | | | |||
| Sven A. Wehrwein | | | 70 | | | 2011 | | | Yes | | | ![]() | | | | | | ![]() | |
![]() | | | Chairperson | |
![]() | | | Member | |
• | Separate Board Chairperson and CEO |
• | Risk oversight by full Board and Committees |
• | Majority voting standard for uncontested director elections |
• | Annual election of directors |
• | By-laws provide for Proxy Access by shareholders |
• | Annual advisory say-on-pay vote |
• | Teamwork – We are dedicated to the idea that a diversity of minds is better than one. Through open communication, we strive to collaborate with and include all of our colleagues to maximize our creativity and to make our good ideas great. We respect each other’s opinions. We help colleagues who are struggling to improve, so our success is everyone’s success. |
• | Trust – Our integrity is built on honest answers to our customers and colleagues. It is okay to make mistakes if we use them to learn. We navigate difficult situations with compassion. The success of our Company depends on the success of our people. |
• | Achievement – Speed and innovation are the cornerstones of our success. We are committed to being a solution for getting things done quickly and sustainably and a catalyst for great ideas for our shareholders, customers, the environment and each other. We are responsible for our performance, our results and our future. |
| | | Proposal | | | Board’s Voting Recommendation | | |
| 1. | | | Election of the eight director nominees named in this Proxy Statement to serve for one-year terms. | | | For | |
| 2. | | | Ratification of the selection of Ernst & Young LLP as our independent accounting firm for fiscal 2021. | | | For | |
| 3. | | | Advisory vote to approve the executive officer compensation disclosed in this Proxy Statement (“say-on-pay”). | | | For | |
Q: | Who can vote? |
A: | You can vote if you were a shareholder at the close of business on the record date of March 23, 2021 (the “Record Date”). There were a total of 27,689,746 shares of our common stock outstanding on the Record Date. The Notice of Internet Availability of Proxy Materials (the “Notice”), notice of annual meeting, this Proxy Statement and accompanying proxy card and the Annual Report on Form 10-K for 2020 were first mailed or made available to you beginning on or about April 6, 2021. This Proxy Statement summarizes the information you need to vote at the Annual Meeting. |
Q: | Who can attend the Annual Meeting? |
A: | This year, the 2021 Annual Meeting will once again be conducted exclusively virtually via live webcast at www.virtualshareholdermeeting.com/PRLB21 (the “Annual Meeting Website”). All shareholders, regardless of size, resources or physical location, eligible to attend the Annual Meeting will be able to participate via webcast and will be able to communicate with us and ask questions before and during the Annual Meeting. All shareholders as of the Record Date, or their duly appointed proxies, may attend the Annual Meeting. If you hold your shares in street name, then you must request a legal proxy from your broker or nominee to attend and vote at the Annual Meeting. |
Q: | What am I voting on? |
A: | You are voting on: |
• | Election of eight nominees as directors to hold office until the next Annual Meeting of Shareholders or until their successors are duly elected. |
• | Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for fiscal 2021. |
• | Approval on an advisory basis of the compensation of our officers disclosed in this Proxy Statement, which we refer to as a “say-on-pay” vote. |
Q: | How does the board of directors recommend I vote on the proposals? |
A: | The board is soliciting your proxy and recommends you vote: |
• | FOR each of the director nominees; |
• | FOR the ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for fiscal 2021; and |
• | FOR the say-on-pay proposal. |
Q: | Why did I receive a notice in the mail regarding the Internet availability of proxy materials instead of a paper copy of the proxy materials? |
A: | “Notice and Access” rules adopted by the United States Securities and Exchange Commission (the “SEC”) permit us to furnish proxy materials, including this Proxy Statement and our Annual Report on Form 10-K for 2020, to our shareholders by providing access to such documents on the Internet instead of mailing printed copies. Shareholders will not receive printed copies of the proxy materials unless they request them. Instead, the Notice instructs as to how you may access and review all of the proxy materials on the Internet. |
Q: | How many shares must be voted to approve each proposal? |
A: | Quorum. A majority of the shares entitled to vote, represented in person or by proxy, is necessary to constitute a quorum for the transaction of business at the Annual Meeting. As of the Record Date, 27,689,746 shares of our common stock were issued and outstanding. A majority of those shares will constitute a quorum for the purpose of electing directors and adopting proposals at the Annual Meeting. If you submit a valid proxy or attend the Annual Meeting, your shares will be counted to determine whether there is a quorum. |
Q: | What is the effect of broker non-votes and abstentions? |
A: | A “broker non-vote” occurs when a nominee holding shares for a beneficial owner does not vote on a particular proposal because the nominee does not have or does not exercise discretionary voting power with respect to that item and has not received voting instructions from the beneficial owner. If a broker returns a “non-vote” proxy indicating a lack of authority to vote on a proposal, then the shares covered by such a “non-vote” proxy will be deemed present at the Annual Meeting for purposes of determining a quorum, but not present for purposes of calculating the vote with respect to any non-discretionary proposals. Nominees will not have discretionary voting power with respect to any matter to be voted upon at the Annual Meeting, other than the ratification of the selection of our independent registered public accounting firm. Broker non-votes will have no effect on the election of directors, the ratification of the independent registered accounting firm, approval of the advisory say-on-pay resolution, or any other item properly presented at the Annual Meeting or any adjournments or postponements thereof. |
Q: | How will the proxies vote on any other business brought up at the Annual Meeting? |
A: | By submitting your proxy, you authorize the proxies to use their judgment to determine how to vote on any other matter brought before the Annual Meeting, or any adjournments or postponements thereof. We do not know of any other business to be considered at the Annual Meeting. The proxies’ authority to vote according to their judgment applies only to shares you own as the shareholder of record. |
Q: | How do I cast my vote? |
A: | If you are a shareholder whose shares are registered in your name, you may vote using any of the following methods: |
• | Internet. You may vote by going to the web address www.proxyvote.com 24-hours a day, seven days a week, until 11:59 p.m. Eastern Time on May 17, 2021 and following the instructions for Internet voting shown on your proxy card. |
• | Telephone. If you requested printed proxy materials and you received a paper copy of the proxy card, you may vote by dialing 1-800-690-6903 24-hours a day, seven days a week, until 11:59 p.m. Eastern Time on May 17, 2021 and following the instructions for telephone voting shown on your proxy card. |
• | Mail. If you requested printed proxy materials and you receive a paper copy of the proxy card, then you may vote by completing, signing, dating and mailing the proxy card in the envelope provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717. If you vote by Internet or telephone, please do not mail your proxy card. |
• | Virtually at the Annual Meeting Website. If you are a shareholder whose shares are registered in your name, you may vote virtually via live webcast at www.virtualshareholdermeeting.com/PRLB21. |
Q: | Can I vote my shares by filling out and returning the Notice? |
A: | No. The Notice identifies the items to be voted on at the Annual Meeting, but you cannot vote by marking the Notice and returning it. The Notice provides instructions on how to vote by Internet, by requesting and returning a paper proxy card or voting instruction card, or by voting at the Annual Meeting. |
Q: | Can I revoke or change my vote? |
A: | You can revoke your proxy at any time before it is voted at the Annual Meeting by: |
• | submitting a new proxy with a more recent date than that of the first proxy given before 11:59 P.M. Eastern Time on May 17, 2021 by (1) following the Internet voting instructions or (2) following the telephone voting instructions; |
• | completing, signing, dating and returning a new proxy card to us, which must be received by us before the time of the Annual Meeting; or |
• | participating in the virtual Annual Meeting and revoking the proxy by voting those shares when joining the meeting. |
Q: | Who will count the votes? |
A: | Broadridge Financial Solutions, Inc., our independent proxy tabulator, will count the votes. John Way, our Chief Financial Officer, will act as inspector of election for the Annual Meeting. |
Q: | Is my vote confidential? |
A: | All proxies and all vote tabulations that identify an individual shareholder are confidential. Your vote will not be disclosed except: |
• | To allow Broadridge Financial Solutions, Inc. to tabulate the vote; |
• | To allow John Way to certify the results of the vote; and |
• | To meet applicable legal requirements. |
Q: | What shares are included on my proxy? |
A: | Your proxy will represent all shares registered to your account in the same social security number and address. |
Q: | What happens if I don’t vote shares that I own? |
A: | For shares registered in your name. If you do not vote shares that are registered in your name by voting online at the Annual Meeting or by proxy through the Internet, telephone or mail, your shares will not be counted in determining the presence of a quorum or in determining the outcome of the vote on the proposals presented at the Annual Meeting. |
Q: | What if I do not specify how I want my shares voted? |
A: | If you are a registered shareholder and submit a signed proxy card or submit your proxy by Internet or telephone but do not specify how you want to vote your shares on a particular matter, we will vote your shares as follows: |
• | FOR each of the director nominees; |
• | FOR the ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for fiscal 2021; and |
• | FOR the say-on-pay proposal. |
Q: | What does it mean if I get more than one Notice or proxy card? |
A: | Your shares are probably registered in more than one account. You should provide voting instructions for all Notices and proxy cards you receive. |
Q: | How many votes can I cast? |
A: | You are entitled to one vote per share on all matters presented at the Annual Meeting or any adjournment or postponement thereof. There is no cumulative voting. |
Q: | When are shareholder proposals and nominees due for the 2022 Annual Meeting of Shareholders? |
A: | If you want to submit a shareholder proposal or nominee for the 2022 Annual Meeting of Shareholders, you must submit the proposal in writing to our Secretary, Proto Labs, Inc., 5540 Pioneer Creek Drive, Maple Plain, Minnesota 55359, so it is received by the relevant dates set forth below under “Submission of Shareholder Proposals and Nominations.” |
Q: | What is “householding”? |
A: | We may send a single Notice, as well as other shareholder communications, to any household at which two or more shareholders reside unless we receive other instruction from you. This practice, known as “householding,” is designed to reduce duplicate mailings and printing and postage costs, and conserve natural resources. If your Notice is being householded and you wish to receive multiple copies of the Notice, or if you are receiving multiple copies and would like to receive a single copy, or if you would like to opt out of this practice for future mailings, you may contact: |
Q: | How is this proxy solicitation being conducted? |
A: | We will pay for the cost of soliciting proxies and we will reimburse brokerage houses and other custodians, nominees and fiduciaries for their reasonable out-of-pocket expenses for forwarding proxy and solicitation materials to our shareholders. In addition, some of our employees may solicit proxies. We may solicit proxies in person, via the Internet, by telephone and by mail. Our employees will not receive special compensation for these services, which the employees will perform as part of their regular duties. |
• | each person or group who is known by us to own beneficially more than 5% of our outstanding shares of common stock; |
• | each of our named executive officers named in the Summary Compensation Table below; |
• | each of our directors and each director nominee; and |
• | all of the executive officers, directors and director nominees as a group. |
| Name and Address of Beneficial Owner | | | Beneficial Ownership on March 23, 2021 | | |||
| Greater than 5% shareholders: | | | Number | | | Percent | |
| BlackRock, Inc. | | | | | | ||
| 55 East 52nd Street | | | | | | ||
| New York, NY 10055 | | | 4,349,159(1) | | | 15.7% | |
| | | | | | |||
| ARK Investment Management LLC | | | | | | ||
| 3 East 28th Street, 7th Floor | | | | | | ||
| New York, NY 10016 | | | 4,119,922(2) | | | 14.9% | |
| | | | | | |||
| Brown Capital Management, LLC | | | | | | ||
| 1201 N. Calvert Street | | | | | | ||
| Baltimore, MD 21202 | | | 3,704,897(3) | | | 13.4% | |
| | | | | | |||
| The Vanguard Group | | | | | | ||
| 100 Vanguard Blvd. | | | | | | ||
| Malvern, PA 19355 | | | 2,743,050(4) | | | 9.9% | |
| | | | | | |||
| Harding Loevner LP | | | | | | ||
| 400 Crossings Blvd. Fourth Floor | | | | | | ||
| Bridgewater, NJ 08807 | | | 1,601,298(5) | | | 5.8% | |
| | | | | | |||
| Sumitomo Mitsui Trust Holdings, Inc. | | | | | | ||
| 1-4-1 Marunouchi | | | | | | ||
| Chiyoda-ku, Tokyo 100-8233, Japan | | | 1,590,903(6) | | | 5.7% | |
| | | | | | | ||
| Riverbridge Partners LLC | | | | | | ||
| 80 South Eighth St., Suite 1200 | | | | | | ||
| Minneapolis, MN 55402 | | | 1,358,899(7) | | | 4.9% | |
| | | | | | |||
| Directors and named executive officers: | | | | | | ||
| Archie C. Black | | | 8,309(8) | | | * | |
| Sujeet Chand | | | 6,744(9) | | | * | |
| Moonhie Chin | | | 2,187(10) | | | * | |
| Rainer Gawlick | | | 28,314(11) | | | * | |
| John B. Goodman | | | 12,586(12) | | | * | |
| Donald Krantz | | | 6,744(13) | | | * | |
| Sven A. Wehrwein | | | 20,441(14) | | | * | |
| Victoria M. Holt | | | 59,891(15) | | | * | |
| John A. Way | | | 36,057(16) | | | * | |
| Arthur R. Baker III | | | 19,489(17) | | | * | |
| Robert Bodor | | | 27,278(18) | | | * | |
| Bjoern Klaas | | | 4,201(19) | | | * | |
| All directors and executive officers as a group (12 persons) | | | 232,241(20) | | | * | |
* | Represents beneficial ownership of less than one percent |
(1) | Information is based on a Schedule 13G/A filed with the SEC by BlackRock, Inc. (“BlackRock”) on January 25, 2021. BlackRock has sole voting power over 4,277,388 shares of our common stock and sole dispositive power over 4,349,159 shares of our common stock. |
(2) | Information is based on a Schedule 13G/A filed with the SEC by ARK Investment Management LLC (“ARK”) on February 16, 2021. ARK has sole voting power over 3,584,210 shares of our common stock, shared voting power over 346,687 shares of our common stock and sole dispositive power over 4,119,922 shares of our common stock. |
(3) | Information is based on a Schedule 13G/A filed with the SEC by Brown Capital Management, LLC (“Brown”) on February 12, 2021. Brown has sole voting power over 2,357,871 shares of our common stock and sole dispositive power over 3,704,897 shares of our common stock. |
(4) | Information is based on a Schedule 13G/A filed with the SEC by Vanguard Group Inc. (“Vanguard”) on February 8, 2021. Vanguard has shared voting power over 61,453 shares of our common stock, sole dispositive power over 2,661,174 shares of our common stock and shared dispositive power over 81,876 shares of our common stock. |
(5) | Information is based on a Schedule 13G/A filed with the SEC by Harding Loevner LP (“Harding”) on February 16, 2021. Harding has sole voting power over 1,601,298 shares of our common stock and sole dispositive power over 1,601,298 shares of our common stock. |
(6) | Information is based on a Schedule 13G/A filed with the SEC by Sumitomo Mitsui Trust Holdings, Inc. (“Sumitomo”) on February 5, 2021. Sumitomo has shared voting power over 1,590,903 shares of our common stock and shared dispositive power over 1,590,903 shares of our common stock. |
(7) | Information is based on a Schedule 13G/A filed with the SEC by Riverbridge Partners LLC (“Riverbridge”) on January 25, 2021. Riverbridge has sole voting power over 1,031,711 shares of our common stock and sole dispositive power over 1,358,899 shares of our common stock. |
(8) | Includes 1,197 shares of deferred stock units that vest on May 18, 2021 and will be settled after separation from service on the board of directors. |
(9) | Includes 1,197 shares of deferred stock units that vest on May 18, 2021 and will be settled after separation from service on the board of directors. |
(10) | Includes 1,197 shares of deferred stock units that vest on May 18, 2021 and will be settled after separation from service on the board of directors. |
(11) | Includes 4,055 shares that Dr. Gawlick has the right to acquire from us within 60 days of the date of the table pursuant to the exercise of stock options and 1,197 shares of deferred stock units that vest on May 18, 2021 and will be settled after separation from service on the board of directors. |
(12) | Includes 1,197 shares of deferred stock units that vest on May 18, 2021 and will be settled after separation from service on the board of directors. |
(13) | Includes 1,197 shares of restricted stock units that vest on May 18, 2021. |
(14) | Includes 6,055 shares that Mr. Wehrwein has the right to acquire from us within 60 days of the date of the table pursuant to the exercise of stock options and 1,197 shares of deferred stock units that vest on May 18, 2021 and will be settled after separation from service on the board of directors. |
(15) | Includes 18,725 shares that Ms. Holt has the right to acquire from us within 60 days of the date of the table pursuant to the exercise of stock options. |
(16) | Includes 15,277 shares that Mr. Way has the right to acquire from us within 60 days of the date of the table pursuant to the exercise of stock options. |
(17) | Includes 6,669 shares that Mr. Baker has the right to acquire from us within 60 days of the date of the table pursuant to the exercise of stock options and 821 shares of restricted stock units that vest on May 4, 2021. |
(18) | Includes 18,796 shares that Dr. Bodor has the right to acquire from us within 60 days of the date of the table pursuant to the exercise of stock options. |
(19) | Includes 1,679 shares that Mr. Klaas has the right to acquire from us within 60 days of the date of the table pursuant to the exercise of stock options. |
(20) | Includes 71,256 shares held by our executive officers and directors, in the aggregate, that can be acquired from us within 60 days of the date of the table pursuant to the exercise of stock options, 7,182 shares of deferred stock units, in the aggregate, that vest on May 18, 2021 and will be settled after separation from service on the board of directors, 821 shares of restricted stock units that vest on May 4, 2021 and 1,197 shares of restricted stock units that vest on May 18, 2021. |
• | presides at all meetings of the board of directors, including executive sessions of the independent directors; |
• | conducts the annual performance review of the Chief Executive Officer, with input from the other independent directors; |
• | sets the board agenda and frequency of meetings, in consultation with the committee chairs as applicable; and |
• | has the authority to convene meetings of the independent directors at every meeting. |
| Audit Committee | | | Compensation Committee | | | Nominating and Governance Committee | |
| Sven A. Wehrwein (chair) | | | Rainer Gawlick (chair) | | | Sujeet Chand (chair) | |
| Rainer Gawlick | | | Archie C. Black | | | Moonhie Chin | |
| John B. Goodman | | | John B. Goodman | | | Sven A. Wehrwein | |
• | oversees management’s processes for ensuring the quality and integrity of our consolidated financial statements, our accounting and financial reporting processes, and other financial information provided by us to any governmental body or to the public; |
• | evaluates the qualifications, independence and performance of our independent auditor and internal audit function; |
• | oversees the resolution of any disagreements between management and the auditors regarding financial reporting; |
• | oversees our investment and cash management policies; and |
• | supervises management’s processes for ensuring our compliance with legal, ethical and regulatory requirements as set forth in policies established by our board of directors. |
• | identifies qualified individuals to become board members, consistent with criteria approved by the board; |
• | selects director nominees for the next Annual Meeting of Shareholders; |
• | determines the composition of the board’s committees and evaluates and enhances the effectiveness of the board and individual directors and officers; |
• | develops and implements the corporate governance guidelines for our Company; and |
• | ensures that succession planning takes place for critical senior management positions. |
• | reviews and approves compensation programs, awards and employment arrangements for executive officers; |
• | administers compensation plans for employees; |
• | reviews our programs and practices relating to leadership development and continuity; and |
• | determines the compensation of non-employee directors. |
| ![]() Robert Bodor - Age 48 Director since 2021 | Dr. Bodor has served as our President and Chief Executive Officer since March 2021. Dr. Bodor previously served as our Vice President and General Manager – Americas from January 2015 to March 2021. From July 2013 to January 2015, Dr. Bodor served as our Chief Technology Officer. From December 2012 to June 2013, Dr. Bodor served as our Director of Business Development. Prior to joining Proto Labs, from January 2011 to December 2012, Dr. Bodor held several roles at Honeywell, most recently leading SaaS business offerings for Honeywell’s Life Safety Division. Skills and Qualifications Dr. Bodor’s extensive leadership and operating experience provides important perspective to our board of directors. Dr. Bodor brings extensive knowledge in business and product development. As Chief Executive Officer, Dr. Bodor is also is responsible for determining our strategy, articulating priorities and managing our continued growth. | |
| ![]() Archie C. Black - Age 59 Director since 2016 Committees Compensation | Mr. Black has served as a director of our Company since March 2016 and Chairman of the board since May 2020. Mr. Black also serves on the compensation committee. Since 2001, Mr. Black has served as the President and Chief Executive Officer of SPS Commerce, Inc., a provider of cloud-based supply chain management solutions, where he also serves as a director. Prior to joining SPS Commerce, Inc., Mr. Black was a Senior Vice President and Chief Financial Officer at Investment Advisors, Inc. Prior to his time at Investment Advisors, Inc., Mr. Black spent three years at PricewaterhouseCoopers. Skills and Qualifications Mr. Black contributes to our board’s extensive management, financial, and operational experience. During his time as President and Chief Executive Officer at SPS Commerce, Inc., Mr. Black led the transformation of a tech-driven startup company into a global business and developed a deep knowledge of the requirements involved with being a public company. Other Current U.S. Public Company Board Memberships: SPS Commerce, Inc. | |
| ![]() Sujeet Chand - Age 63 Director since 2017 Committees Nominating & Governance (Chair) | Dr. Chand has been the Senior Vice President and Chief Technology Officer at Rockwell Automation, Inc. since 2005. Prior to taking on his current role, Mr. Chand served in various leadership positions at Rockwell. Mr. Chand has sat on multiple government, industry, and higher education advisory boards, and has long had significant interaction with the board of directors of Rockwell. Mr. Chand earned a Doctor of Philosophy degree in electrical and computer engineering and a master's degree in electrical engineering from the University of Florida. Skills and Qualifications Mr. Chand’s qualifications to serve on our board of directors include, among other skills and qualifications, his deep technical expertise and industry knowledge, particularly his experience at Rockwell. Mr. Chand brings a highly effective balance of strategic insight and technical engineering skills, as well as a unique perspective on technology, innovation and customer needs. He has previously served on the boards of the National Institute for Standards and Technology (NIST), National Electrical Manufacturers Association (NEMA), FIRST Robotics, Wisconsin Technology Council, University of Wisconsin Foundation, and Robert W. Baird Venture Partners. He has also represented the U.S. as the head of a delegation to Intelligent Manufacturing Systems, a worldwide consortium on manufacturing technology. Other Current U.S. Public Company Board Memberships: Flowserve Corporation | |
| ![]() Moonhie Chin - Age 63 Director since 2019 Committees Nominating & Governance | Ms. Chin was employed at Autodesk from 1989 to 2019 and held multiple leadership positions including most recently, Senior Vice President of Digital Platform and Experience. Autodesk is a global leader in design, construction, and entertainment software with more than 200 million customers. Her expertise extends to general management, business model transformation from perpetual license to subscription, digital platforms, extracting business insights from advanced analytics, global multi-channel models, global customer support and operations, strategic planning, and corporate governance. Prior to joining Autodesk, she worked for the General Electric Company which she joined after earning her B.S. from the Columbia University School of Engineering and Applied Sciences. Skills and Qualifications Ms. Chin has an exceptional track record of unifying organizations around a mission, incubating and driving new initiatives to optimize business efficiencies and applying intellectual rigor to solve complex challenges. She is a recognized mentor to emerging leaders, especially women in technology, and is engaged in leadership opportunities that promote a culture of excellence, positive team dynamics, and personal and professional development. | |
| ![]() Rainer Gawlick - Age 53 Director since 2008 Committees Audit Compensation (Chair) | Dr. Gawlick serves on the boards of Chyronhego, Sectigo, Cloudsense, SingleDigits and Progress, a publicly traded company, where he is also a member of the audit committee. Previously, from July 2015 to October 2016, Dr. Gawlick was President of Perfecto Mobile, Ltd., a leader in mobile testing. Prior to that he was with IntraLinks, Inc., a computer software company providing virtual data rooms and other content management services, where he served as Executive Vice President of Global Sales. From August 2008 to April 2012, Dr. Gawlick served as Chief Marketing Officer of Sophos Ltd, a computer security company providing endpoint, network and data protection software. From April 2005 to August 2008, Dr. Gawlick served as Vice President of Worldwide Marketing and Strategy at SolidWorks Corp., a CAD software company. He also has held a variety of executive positions in other technology businesses and was a consultant with McKinsey & Company. Skills and Qualifications Dr. Gawlick has extensive sales, marketing and product-management experience in the technology industry. Dr. Gawlick offers expertise in building brand awareness, managing marketing and sales on a global scale and developing growth strategies, which enables him to counsel our Company on our on-going growth initiatives. In addition, Dr. Gawlick has extensive business experience in Japan and Europe, which are our key international markets. Other Current U.S. Public Company Board Memberships: Progress | |
| ![]() John B. Goodman - Age 61 Director since 2001 Committees Audit Compensation | Mr. Goodman currently serves on the board of directors of Inclined Biomedical Technologies, Inc. d/b/a Dribank Labs. From December 1982 to October 2010, Mr. Goodman held various positions at Entegris, Inc., a materials supplier, most recently as Senior Vice President and Chief Technology & Innovation Officer. Skills and Qualifications Mr. Goodman’s technical background and experiences in supply chain networks, logistics and financial planning and reviews enable Mr. Goodman to provide guidance and counsel on our strategic plan, research and development, supplier relationships and finance functions. | |
| ![]() Donald G. Krantz - Age 66 Director since 2017 | Dr. Krantz is currently an associate at Digi Labs, a Wayzata-based technology incubator. He serves on the advisory board for Activated Research Company, a maker of catalysis-based instruments. Dr. Krantz served as our Executive Vice President and Technology Officer from January 2015 until his retirement in June 2016. From January 2007 to January 2015, Dr. Krantz served as our Chief Operating Officer. From November 2005 to January 2007, Dr. Krantz served as our Vice President of Development. Prior to joining our Company, Dr. Krantz served in various roles at MTS Systems, Inc., a builder of custom precision testing and advanced manufacturing systems, including as a business unit Vice President, Vice President of Engineering, and most recently, Chief Technology Officer. Dr. Krantz was an Engineering Fellow at Alliant Techsystems and Honeywell, Inc., and was named the 2005 Distinguished Alumnus of the Department of Computer Science and Engineering at the University of Minnesota. In 2016, he was named a “Titan of Technology” by the Minneapolis/St. Paul Business Journal. Skills and Qualifications Dr. Krantz's knowledge of and experience in leadership positions within multiple departments of our Company, as well as his education and experience, enable him to provide guidance and counsel on strategy, relationships, general business matters and risk management. | |
| ![]() Sven A. Wehrwein - Age 70 Director since 2011 Committees Audit (Chair) Nominating & Governance | Mr. Wehrwein served as Chairman of the board from May 2017 to May 2020. Mr. Wehrwein has been an independent financial consultant to emerging companies since 1999. During his over 35 years in accounting and finance, Mr. Wehrwein has experience as a certified public accountant (inactive), investment banker to emerging growth companies, chief financial officer, and audit committee chair. In addition to his current public company memberships, Mr. Wehrwein has also served on the board of directors of Compellent Technologies, Inc. from 2007 until its acquisition by Dell Inc. in 2011, on the board of Vital Images, Inc. from 1997 until its acquisition by Toshiba Medical in 2011, on the board of Synovis Life Technologies, Inc. from 2004 until its acquisition by Baxter International, Inc. in 2012, on the board of Cogentix Medical, Inc. from 2006 to 2016, and on the board of Image Sensing Systems, Inc. from 2006 to 2012. Skills and Qualifications Mr. Wehrwein’s qualifications to serve on our board of directors include, among other skills and qualifications, his capabilities in financial understanding, strategic planning and auditing expertise, given his experiences in investment banking and in financial leadership positions. As chairman of the audit committee, Mr. Wehrwein also keeps the board abreast of current audit issues and collaborates with our independent auditors and senior management team. Other U.S. Public Company Board Memberships in Past Five Years: Atricure, Inc. SPS Commerce, Inc. Cogenix Medical, Inc. (2006 – 2016) | |
| THE BOARD UNANIMOUSLY RECOMMENDS THAT SHAREHOLDERS VOTE “FOR” EACH NOMINEE LISTED. | |
• | Victoria M. Holt, our President and Chief Executive Officer, or CEO; |
• | John A. Way, our Chief Financial Officer, or CFO, and Executive Vice President of Development; |
• | Arthur R. Baker III, our Chief Technology Officer; |
• | Robert Bodor, our Vice President/General Manager – Americas; and |
• | Bjoern Klaas, our Vice President/General Manager and Managing Director – Europe, Middle East and Africa. |
| Revenue | | | Profitability | | | Cash Generation | |
| $434.4m Revenue decreased to $434.4 million in 2020 compared with $458.7 million in 2019. | | | $1.89 Diluted earnings per share was $1.89 in 2020 as compared to $2.35 in 2019. | | | $107.0m Cash generated from operations during the year totaled $107.0 million as compared to $116.1 million in 2019. | |
| Topic | | | Actions / Decision | | |||
| 2020 Salary Adjustments | | | ✔ | | | Adjusted salaries for each of our named executive officers to better reflect competitive market levels. | |
| | | ✔ | | | As discussed more fully below, our named executive officers voluntarily reduced their base salaries from May 1, 2020 through September 30, 2020 in response to the COVID-19 pandemic. | | |
| | | | | | |||
| 2020 Annual Incentives and Long-Term Incentives | | | ✔ | | | Awarded annual incentives to our named executive officers that averaged 12% of their annual short term incentive for the partial achievement of corporate and regional objectives where applicable. Although it was clear early in calendar year 2020 that the global pandemic would affect our ability to achieve our annual short term incentive targets, we did not lower targets or otherwise adjust our plan. | |
| | | ✔ | | | Granted our named executive officers 2020 equity awards comprised of stock options, restricted stock units (“RSUs”) and performance stock units (“PSUs”). | |
| Topic | | | Actions / Decision | | |||
| Annual Incentive Program Performance Metrics and Design | | | ✔ | | | Continued the use of revenue and adjusted operating income (“AOI”) and added the rollout of our upgraded systems project as bonus a metric. | |
| | | ✔ | | | Maintained the annual incentive plan maximums for 2020 at 200% of the target incentive award. | | |
| PSU Performance Metrics | | | ✔ | | | Changed the performance metrics for our PSU awards on grants going forward, so that performance is measured based on the Company’s three-year cumulative Total Shareholder Return (“TSR”) performance relative to the Russell 2000 Growth Index. | |
| Benchmarking | | | ✔ | | | Reviewed and approved changes to our compensation peer group. | |
| Things We Do | | | Things We Don’t Do | | ||||||
| • | | | “Double-trigger” treatment for cash and accelerated equity vesting upon a change in control | | | • | | | No tax gross-ups on perquisites, severance or change in control payments | |
| • | | | Meaningful stock ownership guidelines for our CEO and executive officers | | | • | | | No hedging/pledging of Proto Labs stock by executive officers | |
| • | | | Requirement that executive officers hold 100% of after-tax shares from option exercises or RSU/PSU vesting until they have achieved their ownership requirement | | | • | | | No option repricing without shareholder approval | |
| • | | | No excessive or additional perquisites unique to named executive officers | | ||||||
| • | | | Continually review our compensation programs to ensure alignment to our shareholder expectations of driving profitable growth | | ||||||
| • | | | Compensation recoupment (“clawback”) policy | | | | | | ||
| • | | | Equity award approval policy | | ||||||
| • | | | Independent compensation committee | | | | ||||
| • | | | Independent compensation consultant | | | | ||||
| • | | | Annual compensation risk assessment | | | |
• | Focus on total compensation for purpose of understanding the competitiveness of executive officer compensation; |
• | Structure the compensation program so as to align the interests of our executive officers with those of our customers, employees, and shareholders; |
• | Provide a competitive total compensation opportunity that includes target incentive goals that are reasonably achievable and aligned to long-term objectives; |
• | Utilize equity-based awards in a manner designed to motivate long-term Company performance, increase shareholder value and emphasize their long-term retentive function; |
• | Recognize and reward the achievement of Company and business unit goals as well as individual performance; |
• | Provide compensation commensurate with the level of business performance achieved; |
• | Provide greater compensation opportunities for individuals who have the most significant responsibilities and therefore the greatest ability to influence our achievement of strategic and operational objectives; |
• | Structure the compensation program so that it is understandable and easily communicated to executives, shareholders and other constituencies; |
• | Place increasing emphasis on incentive/variable compensation for positions of increasing responsibility; and |
• | Make benefit programs available to executive officers consistent with those provided to salaried employees. |
• | First, they identified a pool of potential companies that were U.S.-based, publicly-traded, and were classified in the technology or industrials sectors. |
• | Second, they screened out companies that were outside of approximately one-third to three times that of Proto Labs based on revenue, market capitalization, and employees. |
• | Third, they reviewed company business models, fixed asset turnover, and financial growth statistics in selecting companies that have similar characteristics to Proto Labs. |
| 2019 Peer Group | | | Recommended Changes | | | 2020 Peer Group* | |
| 3D Systems Corporation Axon Enterprise, Inc. Cognex Corporation ESCO Technologies Inc. FARO Technologies, Inc. Monolithic Power Systems, Inc. Power Integrations, Inc. Raven Industries, Inc. RBC Bearings Incorporated Shutterstock, Inc. SPS Commerce, Inc. Sun Hydraulics Corporation Universal Display Corporation Ellie Mae GrafTech International Ltd. | | | (-) Exclusions Ellie Mae GrafTech International Ltd. (+) Additions Badger Meter, Inc. Novanta Inc. | | | 3D Systems Corporation Axon Enterprise, Inc. Cognex Corporation ESCO Technologies Inc. FARO Technologies, Inc. Monolithic Power Systems, Inc. Power Integrations, Inc. Raven Industries, Inc. RBC Bearings Incorporated Shutterstock, Inc. SPS Commerce, Inc. Sun Hydraulics Corporation Universal Display Corporation Badger Meter, Inc. Novanta Inc. | |
| | | | | |
| | | Annual Revenue(1) | | | Market Capitalization(1) | | |
| 25th percentile | | | $403 million | | | $1.3 billion | |
| 75th percentile | | | $654 million | | | $3.7 billion | |
| Proto Labs | | | $451 million | | | $2.7 billion | |
(1) | Amounts shown in this table are for the twelve-month period ended as of the most recently disclosed quarter prior to the 2019 meeting at which Pearl Meyer presented the peer group information to the compensation committee. |
| Compensation Component | | | Form of Compensation | | | Purpose | | |||
| Base Salary | | | Cash | | | • | | | Compensate each named executive officer relative to their individual responsibilities, experience and performance | |
| | | | | • | | | Provide steady cash flow not contingent on short-term variations in Company performance | | ||
| Annual Incentive | | | Cash | | | • | | | Align compensation with our annual corporate financial performance | |
| | | | | • | | | Reward achievement of short-term financial objectives | | ||
| | | | | • | | | Provide participants with a meaningful total cash compensation opportunity (base salary plus annual incentive) | | ||
| Long-Term Incentives | | | Stock Options, Restricted Stock Units and Performance Stock Units | | | • | | | Align compensation with our long-term returns to shareholders | |
| | | • | | | Encourage long-term retention | | ||||
| | | • | | | Create a long-term performance focus | | ||||
| | | • | | | Provide executive ownership opportunities | |
| Name | | | 2020 Annual Base Salary | | | 2019 Annual Base Salary | | | Percentage Change from 2019 Annual Base Salary to 2020 Annual Base Salary | | | Base Pay Percent Reduction from May 1, 2020 to September 30, 2020 | | | Total 2020 Dollar Amount Reduced from May 1, 2020 to September 30, 2020 | |
| Victoria M. Holt | | | $612,000 | | | $600,000 | | | 2% | | | 20% | | | $51,785 | |
| John A. Way | | | $369,685 | | | $362,436 | | | 2% | | | 10% | | | $15,640 | |
| Arthur R. Baker III | | | $318,558 | | | $312,312 | | | 2% | | | 10% | | | $13,477 | |
| Robert Bodor | | | $340,717 | | | $324,492 | | | 5%(1) | | | 10% | | | $14,415 | |
| Bjoern Klaas | | | $328,440 | | | $322,390 | | | 2% | | | 10% | | | $13,685 | |
(1) | The percentage change from 2019 annual base salary to 2020 annual base salary was greater for Dr. Bodor than for our other named executive officers in order to maintain a market competitive position. |
• | 50% of the annual bonus target was based on annual revenue growth, calculated without regard to foreign currency exchange rates. We refer to this aspect of the annual incentive program as the revenue factor. |
• | 25% of the annual bonus target was based on budgeted adjusted operating margin. We refer to this aspect of the annual incentive program as the adjusted operating income (“AOI”) factor. For purposes of calculating attainment of the AOI portion of the annual incentives, AOI is defined as operating income before incentive compensation expense, stock-based compensation expense, amortization expense, acquisition expenses and other one-time expenses not indicative of core operations, calculated as a percentage of revenue. |
• | 25% of the annual bonus target was based on the timely and successful rollout of the updated e-commerce, financial and operating systems implementation. |
| Name | | | Revenue | | | AOI | | |||
| Consolidated | | | Geographic Unit | | | Consolidated | | |||
| Victoria M. Holt | | | 100% | | | | | | 100% | |
| John A. Way | | | 100% | | | | | | 100% | |
| Arthur R. Baker III | | | 100% | | | | | | 100% | |
| Robert Bodor | | | 35% | | | 65% | | | 100% | |
| Bjoern Klaas | | | 35% | | | 65% | | | 100% | |
| Name | | | Target Payout as % of 2020 Salary | |
| Victoria M. Holt | | | 100% | |
| John A. Way | | | 75% | |
| Arthur R. Baker III | | | 50% | |
| Robert Bodor | | | 60% | |
| Bjoern Klaas | | | 50% | |
• | For consolidated revenue performance between threshold and target, the payout factor would increase proportionately between 30% and 100%, or about 1.8 percentage points for each $1 million in additional consolidated revenue, and between target and maximum, the payout factor would increase proportionately between 100% and 200%, or about 2.5 percentage points for each $1 million in additional consolidated revenue. |
• | For United States revenue performance between threshold and target, the payout factor would increase proportionately between 30% and 100%, or about 2.4 percentage points for each $1 million in additional United States revenue, and between target and maximum, the payout factor would increase proportionately between 100% and 200%, or about 3.5 percentage points for each $1 million in additional consolidated revenue. |
• | For EMEA revenue performance between threshold and target, the payout factor would increase proportionately between 30% and 100%, or about 9.1 percentage points for each $1 million in additional EMEA revenue, and between target and maximum, the payout factor would increase proportionately between 100% and 200%, or about 13.0 percentage points for each $1 million in additional consolidated revenue. |
| Objective(1) | | | 2020 Target Growth (%) | | | 2020 Target Amount ($) | |
| Consolidated Revenue Growth | | | 8.4% | | | $500.0M | |
| United States Revenue Growth | | | 7.9% | | | $389.0M | |
| EMEA Revenue Growth | | | 12.3% | | | $98.3M | |
| Consolidated Adjusted Operating Income | | | 21.5% | | | — | |
| United States Adjusted Operating Income | | | 21.5% | | | — | |
| EMEA Adjusted Operating Income | | | 23.3% | | | — | |
| Protolabs 2.0 | | | — | | | — | |
(1) | The final payout factor for 2020 was based on the dollar amount of actual performance, as opposed to the growth percentage. |
| Objective | | | Actual Performance(1) | | | Final Payout Factor | |
| Consolidated Revenue(2) | | | $433.3M | | | 0.0% | |
| United States Revenue(3) | | | $345.4M | | | 0.0% | |
| EMEA Revenue(4) | | | $79.8M | | | 0.0% | |
| Consolidated Adjusted Operating Income | | | 19.3% | | | 47.8% | |
| United States Adjusted Operating Income | | | 19.7% | | | 56.3% | |
| EMEA Adjusted Operating Income | | | 20.6% | | | 54.4% | |
| Protolabs 2.0 | | | — | | | 0.0% | |
(1) | Our actual performance is equal to our 2020 revenue calculated using 2020 budgeted foreign currency exchange rates. Actual AOI performance is listed as adjusted operating margin achieved in 2020. |
(2) | For consolidated revenue performance between threshold and target, the payout factor would increase proportionately between 30% and 100%, or about 1.8 percentage points for each $1 million in additional consolidated revenue. |
(3) | For United States revenue performance between threshold and target, the payout factor would increase proportionately between 30% and 100%, or about 2.4 percentage points for each $1 million in additional United States revenue. |
(4) | For EMEA revenue performance between threshold and target, the payout factor would increase proportionately between 30% and 100%, or about 9.1 percentage points for each $1 million in additional EMEA revenue. |
| Name | | | 2020 Actual Incentive Amount ($) | | | Percent of Annual Incentive Target Achieved (%) | |
| Victoria M. Holt | | | $73,440 | | | 12% | |
| John A. Way | | | $33,272 | | | 12% | |
| Arthur R. Baker III | | | $19,113 | | | 12% | |
| Robert Bodor | | | $24,900 | | | 12% | |
| Bjoern Klaas | | | $20,318 | | | 12% | |
| Name | | | Aggregate Grant Date Fair Value of 2020 Equity Awards | | | Number of RSUs Awarded | | | Number of Stock Options Awarded | | | Target Number of PSUs Awarded | |
| Victoria M. Holt | | | $2,739,286 | | | 8,530 | | | 10,187 | | | 12,551 | |
| John A. Way | | | $943,144 | | | 4,607 | | | 5,501 | | | 2,259 | |
| Arthur R. Baker III | | | $628,758 | | | 3,071 | | | 3,668 | | | 1,506 | |
| Robert Bodor | | | $628,758 | | | 3,071 | | | 3,668 | | | 1,506 | |
| Bjoern Klaas | | | $419,222 | | | 2,048 | | | 2,445 | | | 1,004 | |
| Relative TSR Percentile | | | PSU Payout (% of Target) | |
| Below 25th percentile | | | 0% | |
| 25th percentile | | | 50% | |
| 50th percentile | | | 100% | |
| 75th percentile or greater | | | 150% | |
| Performance Level | | | 2020 Organic Revenue | | | Revenue Payout Factor | | | 2020 Adjusted EPS | | | EPS Payout Factor | |
| Threshold | | | $540,000,000 | | | 25% | | | $4.01 | | | 25% | |
| Target | | | $607,000,000 | | | 50% | | | $4.22 | | | 50% | |
| Maximum | | | > $681,000,000 | | | 75% | | | > $4.43 | | | 75% | |
• | the Company will pay Dr. Bodor an amount equal to one times his annualized base salary in substantially equal installments in accordance with the Company’s regular payroll practices over the 12-month period immediately following the termination date, subject to limited exceptions; |
• | the Company will pay Dr. Bodor an amount equal to one times his target annual cash incentive bonus for the calendar year in which his employment with the Company terminates, payable in a lump sum; |
• | if Dr. Bodor was enrolled in a group health plan sponsored by the Company immediately prior to his employment termination, then the Company will pay its share of premiums due for Dr. Bodor and his eligible dependents to continue such coverage under Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”) for the first 12 months of COBRA coverage, if elected by Dr. Bodor; and |
• | if Dr. Bodor has any unvested equity-based awards as of the termination date, a pro rata portion of any time-based unvested awards scheduled to vest on the next anniversary of the grant date will vest immediately based on the number of such equity-based awards that would have vested as of the next anniversary assuming Dr. Bodor would have remained employed through the anniversary, pro-rated based on the number of days Dr. Bodor was employed by the Company during the then-current vesting year divided by the number of days in a year. For performance-based awards, the number of additional shares that will vest as a result of such pro rata vesting will be determined by multiplying the total number of additional shares that would otherwise have been determined to have been earned had Dr. Bodor remained employed through the end of the applicable performance period by a fraction, the numerator of which is the number of days Dr. Bodor was employed by the Company during the performance period and the denominator of which is the number of days in the performance period. |
• | an amount equal to one times his annualized base salary, payable in a lump sum; |
• | an amount equal to one times his target annual cash incentive bonus for the calendar year in which his employment with the Company terminates, payable in a lump sum; |
• | the Company’s share of premiums due for Dr. Bodor and his eligible dependents for an additional six months of coverage under COBRA (after the initial 12-month COBRA coverage period ends), if elected by Dr. Bodor; and |
• | an amount equal to the value of any unvested equity-based awards held by him as of the termination date that were forfeited as of the termination date. In the case of forfeited performance-based awards, the intrinsic value shall be based on the number of shares subject to an award based on a determination by the Board of the degree to which any performance-based vesting or payment conditions will be deemed satisfied. |
• | the Company will pay Dr. Bodor an amount equal to two times his annualized base salary in substantially equal installments in accordance with the Company’s regular payroll practices over the 24-month period immediately following the termination date, subject to limited exceptions; |
• | the Company will pay Dr. Bodor an amount equal to two times his target annual cash incentive bonus for the calendar year in which his employment with the Company terminates, payable in a lump sum; |
• | if Dr. Bodor was enrolled in a group health plan sponsored by the Company immediately prior to his employment termination, then the Company will pay its share of premiums due for Dr. Bodor and his eligible dependents to continue such coverage under COBRA for the first 18 months of COBRA coverage, if elected by Dr. Bodor; and |
• | if Dr. Bodor has any unvested equity-based awards as of the termination date, all such unvested awards will vest immediately on Dr. Bodor’s termination date. In the case of performance-based awards, the number of shares subject to such accelerated vesting shall be based on a determination by the Board of the degree to which any performance-based vesting conditions will be deemed satisfied. |
(1) | All of the following factors are present: |
• | We are required to prepare an accounting restatement due to material noncompliance with any financial reporting requirement under the securities laws; |
• | The award, vesting or payment of the incentive compensation was predicated upon the achievement of certain financial results that were the subject of the restatement and such award, vesting or payment occurred or was received during the three-year period preceding the date on which we were required to prepare the restatement; and |
• | A smaller award, vesting or payment would have occurred or been made to the executive officer based upon the restated financial results. |
(2) | There has been misconduct resulting in either a violation of law or of our Company policy that has caused significant financial or reputational harm to our Company and either the executive officer committed the misconduct or failed in his or her responsibility to manage or monitor the applicable conduct or risks. |
• | CEO – Five times annual base salary |
• | All other executive officers – One times annual base salary |
| Name and Principal Position | | | Year | | | Salary ($) | | | Stock Awards ($)(1) | | | Option Awards ($)(2) | | | Non-Equity Incentive Plan Compensation ($)(3) | | | All Other Compensation ($) (4) | | | Total ($) | |
| Victoria M. Holt President and Chief Executive Officer | | | 2020 | | | 583,292 | | | 2,314,264 | | | 425,022 | | | 73,440 | | | 11,200 | | | 3,407,218 | |
| 2019 | | | 600,000 | | | 2,160,169 | | | 340,034 | | | 215,308 | | | 11,000 | | | 3,326,511 | | |||
| 2018 | | | 550,000 | | | 2,160,155 | | | 340,025 | | | 534,875 | | | 11,000 | | | 3,596,055 | | |||
| John A. Way Chief Financial Officer | | | 2020 | | | 367,985 | | | 713,631 | | | 229,513 | | | 33,272 | | | 11,200 | | | 1,355,601 | |
| 2019 | | | 362,436 | | | 670,677 | | | 229,523 | | | 97,748 | | | 11,000 | | | 1,371,384 | | |||
| 2018 | | | 351,880 | | | 596,113 | | | 204,034 | | | 256,740 | | | 11,000 | | | 1,419,767 | | |||
| Arthur R. Baker III Chief Technology Officer | | | 2020 | | | 317,044 | | | 475,722 | | | 153,036 | | | 19,113 | | | 11,200 | | | 976,115 | |
| 2019 | | | 312,312 | | | 447,048 | | | 153,014 | | | 56,133 | | | 11,000 | | | 979,507 | | |||
| 2018 | | | 300,300 | | | 447,111 | | | 153,014 | | | 146,021 | | | 11,000 | | | 1,057,446 | | |||
| Robert Bodor Vice President/General Manager - Americas | | | 2020 | | | 338,658 | | | 475,722 | | | 153,036 | | | 24,900 | | | 11,200 | | | 1,003,516 | |
| 2019 | | | 324,492 | | | 447,048 | | | 153,014 | | | 59,941 | | | 11,000 | | | 995,495 | | |||
| 2018 | | | 300,456 | | | 417,290 | | | 142,838 | | | 174,965 | | | 11,000 | | | 1,046,549 | | |||
| Bjoern Klaas(5) Vice President and Managing Director - Europe, Middle East and Africa | | | 2020 | | | 324,274 | | | 317,212 | | | 102,010 | | | 20,318 | | | 15,179 | | | 778,993 | |
| 2019 | | | 322,390 | | | 298,066 | | | 102,011 | | | 112,925 | | | 13,863 | | | 849,255 | |
(1) | Amounts shown in this column reflect the aggregate grant date fair value of the RSUs and PSUs (at target) granted in 2020, 2019 and 2018 and are computed in accordance with ASC Topic 718, Compensation—Stock Compensation (ASC 718), based on the closing stock price on the grant date. The grant date fair value of RSUs granted in 2020 and the grant date fair value of the PSUs granted in 2020 if target performance and maximum performance is achieved are as follows: |
| Name | | | RSUs | | | PSUs | | |||
| | | | | Target | | | Maximum | | ||
| Victoria M. Holt | | | $825,022 | | | $1,489,243 | | | $2,233,865 | |
| John A. Way | | | $445,589 | | | $268,042 | | | $402,063 | |
| Arthur R. Baker III | | | $297,027 | | | $178,695 | | | $268,043 | |
| Robert Bodor | | | $297,027 | | | $178,695 | | | $268,043 | |
| Bjoern Klaas | | | $198,083 | | | $119,130 | | | $178,695 | |
(2) | Amounts shown in this column represent the grant date fair values computed in accordance with ASC 718 utilizing the assumptions discussed in Note 12 to our Consolidated Financial Statements for the year ended December 31, 2020 contained in our Annual Report on Form 10-K for the year ended December 31, 2020, and disregarding the effects of any estimates of forfeitures related to service-based vesting. |
(3) | Amounts shown in this column represent amounts earned under our annual incentive program during each respective year and paid early in the following year. |
(4) | Except for Mr. Klaas, amounts shown in this column for all named executive officers for 2020 represent Company contributions to our 401(k) retirement plan. |
(5) | Prior to 2019, Mr. Klaas was not a named executive officer. |
| | | | | Compensation Committee | | | Estimated Future Payouts Under Non-Equity Incentive Plan Awards | | | Estimated Future Payouts Under Equity Incentive Plan Awards (2) | | | All Other Stock Awards: Number of Shares of Stock or Units (#)(3) | | | All Other Option Awards: Number of Securities Underlying Options (#)(4) | | | Exercise or Base Price of Option Awards ($/Sh) | | | Grant Date Fair Value of Stock and Option Awards(5) | | ||||||||||||||
| Name | | | Grant Date | | | Approval Date(1) | | | Threshold ($) | | | Target ($) | | | Maximum ($) | | | Threshold (#) | | | Target (#) | | | Maximum (#) | | ||||||||||||
| Victoria M. Holt | | | $189,570 | | | $583,292 | | | $1,166,584 | | | | | | | | | | | | | | | | |||||||||||||
| | | 2/10/2020 | | | 2/4/2020 | | | | | | | | | | | | | | | 8,530 | | | | | | | $825,022 | | |||||||||
| | | 2/10/2020 | | | 2/4/2020 | | | | | | | | | | | | | | | | | 10,187 | | | 96.72 | | | $425,022 | | ||||||||
| | | 2/12/2020 | | | 2/12/2020 | | | | | | | | | 6,276 | | | 12,551 | | | 18,827 | | | | | | | | | $1,489,243 | | |||||||
| John A. Way | | | $89,696 | | | $275,989 | | | $551,978 | | | | | | | | | | | | |||||||||||||||||
| | | 2/10/2020 | | | 2/4/2020 | | | | | | | | | | | | | | | 4,607 | | | | | | | $445,589 | | |||||||||
| | | 2/10/2020 | | | 2/4/2020 | | | | | | | | | | | | | | | | | 5,501 | | | 96.72 | | | $229,513 | | ||||||||
| | | 2/12/2020 | | | 2/12/2020 | | | | | | | | | 1,130 | | | 2,259 | | | 3,389 | | | | | | | | | $268,042 | | |||||||
| Arthur R. Baker III | | | $51,520 | | | $158,522 | | | $317,044 | | | | | | | | | | | | |||||||||||||||||
| | | 2/10/2020 | | | 2/4/2020 | | | | | | | | | | | | | | | 3,071 | | | | | | | $297,027 | | |||||||||
| | | 2/10/2020 | | | 2/4/2020 | | | | | | | | | | | | | | | | | 3,668 | | | 96.72 | | | $153,036 | | ||||||||
| | | 2/12/2020 | | | 2/12/2020 | | | | | | | | | 753 | | | 1,506 | | | 2,259 | | | | | | | | | $178,695 | | |||||||
| Robert Bodor | | | $66,038 | | | $203,195 | | | $406,390 | | | | | | | | | | | | |||||||||||||||||
| | | 2/10/2020 | | | 2/4/2020 | | | | | | | | | | | | | | | 3,071 | | | | | | | $297,027 | | |||||||||
| | | 2/10/2020 | | | 2/4/2020 | | | | | | | | | | | | | | | | | 3,668 | | | 96.72 | | | $153,036 | | ||||||||
| | | 2/12/2020 | | | 2/12/2020 | | | | | | | | | 753 | | | 1,506 | | | 2,259 | | | | | | | | | $178,695 | | |||||||
| Bjoern Klaas | | | $52,695 | | | $162,137 | | | $324,274 | | | | | | | | | | | | |||||||||||||||||
| | | 2/10/2020 | | | 2/4/2020 | | | | | | | | | | | | | | | 2,048 | | | | | | | $198,083 | | |||||||||
| | | 2/10/2020 | | | 2/4/2020 | | | | | | | | | | | | | | | | | 2,445 | | | 96.72 | | | $102,010 | | ||||||||
| | | 2/12/2020 | | | 2/12/2020 | | | | | | | | | 502 | | | 1,004 | | | 1,506 | | | | | | | | | $119,130 | |
(1) | In accordance with the terms of our equity grant timing policy, the RSUs, PSUs and stock option grants to our named executive officers identified in the table were granted effective as of the end of the second trading day following the public release of our financial results for the fourth quarter of 2019, even though the compensation committee approved the grants on an earlier date. |
(2) | As discussed above in “Compensation Discussion and Analysis—Elements of Executive Compensation,” amounts in this column represent an award of PSUs under the LTIP capable of being earned and vesting at the end of a three-year performance period depending on our Company’s three-year cumulative Total Shareholder Return (“TSR”) performance relative to the Russell 2000 Growth Index and the award recipient’s continued employment. The PSU vesting terms in the event of certain terminations of employment or a change in control of our Company are described above in “Elements of Executive Compensation—Long-Term Equity-Based Compensation.” No dividend equivalents are paid on the PSUs. |
(3) | Amounts in this column represent awards of RSUs under the LTIP which vest as to 25% of the shares in four annual installments beginning on February 13, 2021. Unvested RSUs will immediately vest in full upon the named executive officer’s death or disability and if, within one year of a change in control, the named executive officer’s employment is terminated without cause or for good reason. No dividend equivalents are paid on the RSUs. |
(4) | Amounts in this column represent awards of stock options under the LTIP which vest as to 25% of the shares in four annual installments beginning on February 13, 2021. Unvested options will immediately become vested and exercisable in full upon the named executive officer’s death or disability and if, within one year of a change in control, the named executive officer’s employment is terminated without cause or for good reason. |
(5) | The actual value to be realized by a named executive officer depends upon the appreciation in value of our stock and the length of time the award is held. No value will be realized with respect to any stock option award if our stock price does not increase following the grant date. For a description of the assumptions used in computing grant date fair value for stock option awards pursuant to ASC 718, see Note 12 to our Consolidated Financial Statements for the year ended December 31, 2020 contained in our Annual Report on Form 10-K. The grant date fair value of each RSU award and PSU award (at target) was computed in accordance with ASC 718. |
| | | Option Awards | | | Stock Awards | | ||||||||||||||||||||||
| Name | | | Option Grant Date(1) | | | Number of Securities Underlying Unexercised Options (#) Exercisable | | | Number of Securities Underlying Unexercised Options (#) Unexercisable | | | Option Exercise Price ($/Sh) | | | Option Expiration Date | | | Number of Shares or Units of Stock That Have Not Vested (#) | | | Market Value of Shares or Units of Stock That Have Not Vested ($) (2) | | | Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#) | | | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($)(2) | |
| Victoria M. Holt | | | 02/08/16 | | | 15,128 | | | 3,782 | | | 57.88 | | | 02/08/26 | | | | | | | | | | ||||
| | | 02/13/17 | | | 5,442 | | | 3,628 | | | 58.35 | | | 02/13/27 | | | | | | | | | | |||||
| | | 02/12/18 | | | 3,575 | | | 3,576 | | | 105.75 | | | 02/12/28 | | | | | | | | | | |||||
| | | 02/11/19 | | | 1,780 | | | 5,340 | | | 104.99 | | | 02/11/29 | | | | | | | | | | |||||
| | | 02/10/20 | | | — | | | 10,187 | | | 96.72 | | | 02/10/30 | | | | | | | | | | |||||
| | | | | | | | | | | | | 1,728 | | | 265,075 | | | | | | ||||||||
| | | | | | | | | | | | | 5,142 | | | 788,783 | | | | | | ||||||||
| | | | | | | | | | | | | 3,121 | | | 478,761 | | | | | | ||||||||
| | | | | | | | | | | | | 4,716 | | | 723,434 | | | | | | ||||||||
| | | | | | | | | | | | | 8,530 | | | 1,308,502 | | | | | | ||||||||
| | | | | | | | | | | | | 23,237(3) | | | 3,564,555 | | | | | | ||||||||
| | | | | | | | | | | | | | | | | 14,288 | | | $2,191,779(4) | | ||||||||
| | | | | | | | | | | | | | | | | 12,551 | | | $1,925,323(5) | | ||||||||
| John A. Way | | | 02/08/16 | | | — | | | 2,837 | | | 57.88 | | | 02/08/26 | | | | | | | | | | ||||
| | | 02/13/17 | | | 4,083 | | | 2,722 | | | 58.35 | | | 02/13/27 | | | | | | | | | | |||||
| | | 02/12/18 | | | 2,145 | | | 2,146 | | | 105.75 | | | 02/12/28 | | | | | | | | | | |||||
| | | 02/11/19 | | | 1,201 | | | 3,605 | | | 104.99 | | | 02/11/29 | | | | | | | | | | |||||
| | | 02/10/20 | | | — | | | 5,501 | | | 96.72 | | | 02/10/30 | | | | | | | | | | |||||
| | | | | | | | | | | | | 1,296 | | | 198,806 | | | | | | ||||||||
| | | | | | | | | | | | | 3,858 | | | 591,817 | | | | | | ||||||||
| | | | | | | | | | | | | 1,873 | | | 287,318 | | | | | | ||||||||
| | | | | | | | | | | | | 3,183 | | | 488,272 | | | | | | ||||||||
| | | | | | | | | | | | | 4,607 | | | 706,713 | | | | | | ||||||||
| | | | | | | | | | | | | 14,817(6) | | | 2,272,926 | | | | | | ||||||||
| | | | | | | | | | | | | | | | | 2,144 | | | $328,890(4) | | ||||||||
| | | | | | | | | | | | | | | | | 2,259 | | | $346,531(5) | | ||||||||
| Arthur R. Baker III | | | 05/02/16 | | | 3,474 | | | 1,737 | | | 60.96 | | | 05/02/26 | | | | | | | | | | ||||
| | | 02/13/17 | | | 2,721 | | | 1,814 | | | 58.35 | | | 02/13/27 | | | | | | | | | | |||||
| | | 02/12/18 | | | 1,609 | | | 1,609 | | | 105.75 | | | 02/12/28 | | | | | | | | | | |||||
| | | 02/11/19 | | | 801 | | | 2,403 | | | 104.99 | | | 02/11/29 | | | | | | | | | | |||||
| | | 02/10/20 | | | — | | | 3,668 | | | 96.72 | | | 02/10/30 | | | | | | | | | | |||||
| | | | | | | | | | | | | 821 | | | 125,941 | | | | | | ||||||||
| | | | | | | | | | | | | 2,572 | | | 394,545 | | | | | | ||||||||
| | | | | | | | | | | | | 1,405 | | | 215,527 | | | | | | ||||||||
| | | | | | | | | | | | | 2,122 | | | 325,515 | | | | | | ||||||||
| | | | | | | | | | | | | 3,071 | | | 471,091 | | | | | | ||||||||
| | | | | | | | | | | | | 9,991(7) | | | 1,532,619 | | | | | | ||||||||
| | | | | | | | | | | | | | | | | | 1,429 | | | $219,209(4) | | |||||||
| | | | | | | | | | | | | | | | | 1,506 | | | $231,020(5) | | ||||||||
| Robert Bodor | | | 02/13/14 | | | 1,632 | | | — | | | 78.59 | | | 02/13/24 | | | | | | | | | | ||||
| | | 02/09/15 | | | 3,998 | | | — | | | 67.15 | | | 02/09/25 | | | | | | | | | | |||||
| | | 02/08/16 | | | 3,782 | | | 1,891 | | | 57.88 | | | 02/08/26 | | | | | | | | | | |||||
| | | 02/13/17 | | | 1,814 | | | 1,814 | | | 58.35 | | | 02/13/27 | | | | | | | | | | |||||
| | | 02/12/18 | | | 1,502 | | | 1,502 | | | 105.75 | | | 02/12/28 | | | | | | | | | | |||||
| | | 02/11/19 | | | 801 | | | 2,403 | | | 104.99 | | | 02/11/29 | | | | | | | | | | |||||
| | | 02/10/20 | | | — | | | 3,668 | | | 96.72 | | | 02/10/30 | | | | | | | | | | |||||
| | | | | | | | | | | | | 864 | | | 132,538 | | | | | | ||||||||
| | | | | | | | | | | | | 2,572 | | | 394,545 | | | | | | ||||||||
| | | | | | | | | | | | | 1,311 | | | 201,107 | | | | | | ||||||||
| | | | | | | | | | | | | 2,122 | | | 325,515 | | | | | | ||||||||
| | | | | | | | | | | | | 3,071 | | | 471,091 | | | | | | ||||||||
| | | | | | | | | | | | | 9,940(8) | | | 1,524,796 | | | | | | ||||||||
| | | | | | | | | | | | | | | | | 1,429 | | | $219,209(4) | | ||||||||
| | | | | | | | | | | | | | | | | 1,506 | | | $231,020(5) | |
| | | Option Awards | | | Stock Awards | | ||||||||||||||||||||||
| Name | | | Option Grant Date(1) | | | Number of Securities Underlying Unexercised Options (#) Exercisable | | | Number of Securities Underlying Unexercised Options (#) Unexercisable | | | Option Exercise Price ($/Sh) | | | Option Expiration Date | | | Number of Shares or Units of Stock That Have Not Vested (#) | | | Market Value of Shares or Units of Stock That Have Not Vested ($) (2) | | | Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#) | | | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($)(2) | |
| Bjoern Klaas | | | 02/11/19 | | | 534 | | | 1,602 | | | 104.99 | | | 02/11/29 | | | | | | | | | | ||||
| | | 02/10/20 | | | — | | | 2,445 | | | 96.72 | | | 02/10/30 | | | | | | | | | | |||||
| | | | | | | | | | | | | 2,118 | | | 324,901 | | | | | | ||||||||
| | | | | | | | | | | | | 1,415 | | | 217,061 | | | | | | ||||||||
| | | | | | | | | | | | | 2,048 | | | 314,163 | | | | | | ||||||||
| | | | | | | | | | | | | 5,581(9) | | | 856,125 | | | | | | ||||||||
| | | | | | | | | | | | | | | | | 953 | | | $146,190(4) | | ||||||||
| | | | | | | | | | | | | | | | | 1,004 | | | $154,014(5) | |
(1) | The option awards granted prior to 2018 vest as to 20% of the shares subject to each award in five annual installments on February 13 each year, with the exception of Mr. Baker’s May 2, 2016 grant. Mr. Baker’s award vests on each of the first, second, third, fourth and fifth anniversaries of the date of grant. The option awards granted beginning in 2018 vest as to 25% of the shares subject to each award in four annual installments on February 13 each year. |
(2) | Based on the $153.40 per share closing price of our common stock on the NYSE on December 31, 2020. |
(3) | In the order presented in the table, the RSUs listed vest as to 1,728 shares subject to the units on February 13, 2021, as to 2,571 shares subject to the units on each of February 13, 2021 and 2022, as to 1,560 shares subject to the units on each of February 13, 2021 and 2022, as to 1,571 shares subject to the units on each of February 13, 2021, 2022 and 2023, and as to 2,133 shares subject to the units on each of February 13, 2021, 2022, 2023, and 2024. |
(4) | Performance stock units vest on December 31, 2021 depending on our Company's organic revenue and adjusted EPS performance in the final year of the performance period and the award recipients continued employment. |
(5) | Performance stock units vest on December 31, 2022 depending on our Company’s three-year cumulative Total Shareholder Return (“TSR”) performance relative to the Russell 2000 Growth Index and the award recipients continued employment. |
(6) | In the order presented in the table, the RSUs listed vest as to 1,296 shares subject to the units on February 13, 2021, as to 1,929 shares subject to the units on each of February 13, 2021 and 2022, as to 936 shares subject to the units on each of February 13, 2021 and 2022, as to 1,061 shares subject to the units on each of February 13, 2021, 2022 and 2023, and as to 1,152 shares subject to the units on each of February 13, 2021, 2022, 2023 and 2024. |
(7) | In the order presented in the table, the RSUs listed vest as to 821 shares subject to the units on May 4, 2021, as to 1,286 shares subject to the units on each of February 13, 2021 and 2022, as to 702 shares subject to the units on each of February 13, 2021 and 2022, as to 707 shares subject to the units on each of February 13, 2021, 2022, and 2023, and as to 768 shares subject to the units on each of February 13, 2021, 2022, 2023 and 2024. |
(8) | In the order presented in the table, the RSUs listed vest as to 864 shares subject to the units on February 13, 2021, as to 1,286 shares subject to the units on each of February 13, 2021 and 2022, as to 655 shares subject to the units on each of February 13, 2021 and 2022, as to 707 shares subject to the units on each of February 13, 2021, 2022, and 2023, and as to 768 shares subject to the units on each of February 13, 2021, 2022, 2023 and 2024. |
(9) | In the order presented in the table, the RSUs listed vest as to 1,059 shares subject to the units on each of December 1, 2021 and 2022, as to 471 shares subject to the units on each of February 13, 2021, 2022 and 2023, and as to 512 shares subject to the units on each of February 13, 2021, 2022, 2023 and 2024. |
| | | Option Awards | | | Stock Awards | | |||||||
| Name | | | Number of Shares Acquired on Exercise (#) | | | Value Realized on Exercise ($) (1) | | | Number of Shares Acquired on Vesting (#) | | | Value Realized on Vesting ($) (2) | |
| Victoria M. Holt | | | 17,990 | | | 1,579,499 | | | 15,483 | | | 1,392,952 | |
| John A. Way | | | 15,951 | | | 1,116,604 | | | 5,744 | | | 574,400 | |
| Arthur R. Baker III | | | — | | | — | | | 3,516 | | | 346,855 | |
| Robert Bodor | | | — | | | — | | | 4,035 | | | 403,500 | |
| Bjoern Klaas | | | — | | | — | | | 1,530 | | | 191,484 | |
(1) | The value realized on exercise is calculated as the difference between the closing price of our common stock on the date of exercise as reported by the New York Stock Exchange for the number of shares acquired upon exercise and the applicable option exercise price for those shares. |
(2) | The value realized on vesting is calculated by multiplying the number of shares vested by the closing price of our common stock on the vesting date as reported by the New York Stock Exchange. |
• | we will pay Ms. Holt an amount equal to one times her annualized base salary in substantially equal installments in accordance with our regular payroll practices over the 12-month period immediately following the termination date, subject to limited exceptions; |
• | we will pay Ms. Holt an amount equal to one times her target annual cash incentive payment for the calendar year in which her employment with us terminates, payable in a lump sum; |
• | we will pay our share of premiums due for Ms. Holt and her eligible dependents for the first 12 months of coverage under COBRA if elected by Ms. Holt; and |
• | if Ms. Holt has any unvested equity-based awards as of the termination date, a pro rata portion of any unvested awards scheduled to vest on the next anniversary of the grant date will vest immediately. |
• | we will pay Ms. Holt an amount equal to two times her annualized base salary in substantially equal installments in accordance with our regular payroll practices over the 24-month period immediately following the termination date, subject to limited exceptions; |
• | we will pay Ms. Holt an amount equal to two times her target annual cash incentive payment for the calendar year in which her employment with us terminates, payable in a lump sum; |
• | we will pay our share of premiums due for Ms. Holt and her eligible dependents for the first 18 months of coverage under COBRA if elected by Ms. Holt; and |
• | if Ms. Holt has any unvested equity-based awards as of the termination date, all such unvested awards will vest immediately on Ms. Holt’s termination date. |
• | pay Ms. Holt an amount equal to one times her annualized base salary, payable in a lump sum; |
• | pay Ms. Holt an amount equal to one times her target annual cash incentive payment for the calendar year in which her employment with us terminates, payable in a lump sum; |
• | pay our share of premiums due for Ms. Holt and her eligible dependents for the first six months of coverage under COBRA if elected by Ms. Holt; and |
• | pay Ms. Holt an amount equal to the value of any unvested equity-based awards held by her as of the termination date that were forfeited as of the termination date. |
• | we will pay such officer an amount equal to his annualized base salary in substantially equal installments in accordance with our regular payroll practices over the 12-month period immediately following the termination date, subject to limited exceptions; |
• | we will pay such officer a pro rata cash incentive payment amount, payable in a lump sum; |
• | we will pay our share of premiums due for such officer and his eligible dependents for the first 12 months of coverage under COBRA; and |
• | if such officer has any unvested equity-based awards as of the termination date, a pro rata portion of any unvested awards scheduled to vest on the next anniversary of the grant date will vest immediately. |
• | we will pay such officer an amount equal to his annualized base salary in substantially equal installments in accordance with our regular payroll practices over the 12-month period immediately following the termination date, subject to limited exceptions; |
• | we will pay such officer an amount equal to the sum of (i) his target annual cash incentive payment for the calendar year in which his employment with us terminates plus (ii) a pro rata cash incentive payment amount, payable in a lump sum; |
• | we will pay our share of premiums due for such officer and his eligible dependents for the first 12 months of coverage under COBRA; and |
• | if such officer has any unvested equity-based awards as of the termination date, all such unvested awards will vest immediately on his termination date. |
• | pay such officer an amount equal to his target annual cash incentive payment for the calendar year in which his or her employment with us terminates, payable in a lump sum; and |
• | pay such officer an amount equal to the value of any unvested equity-based awards held by him as of the termination date that were forfeited as of the termination date. |
• | Arrange for the surviving or successor entity to continue, assume or replace some or all of the outstanding awards under the LTIP. |
• | Accelerate the vesting and exercisability of outstanding awards prior to and conditioned upon the occurrence of the event and provide that unexercised options and SARs will be terminated at the effective time of the event. |
• | Cancel any outstanding award in exchange for payment to the holder of the amount of the consideration that would have been received in the event for the number of shares subject to the award, less the aggregate exercise price (if any) of the award. |
• | Provide that if an award is continued, assumed or replaced in connection with such an event and if within 18 months after the event a participant experiences an involuntary termination of service other than for cause, the participant’s outstanding awards will vest in full, will immediately become fully exercisable and will remain exercisable for one year following termination. |
• | Make certain adjustments to awards as provided in the LTIP. |
| Name | | | Termination Without Cause or For Good Reason Not During Transition Period or in Anticipation of Change in Control | | | Termination Without Cause or For Good Reason Upon a Change in Control or During Transition Period(1) | | | Termination Without Cause or For Good Reason in Anticipation of Change in Control(2) | | | Death | | | Disability | | | Change in Control Without Termination | | | Retirement | |
| Victoria M. Holt | | | | | | | | | | | | | | | | |||||||
| Base Salary Payment | | | 583,292 | | | 1,166,584 | | | 583,292 | | | — | | | — | | | — | | | — | |
| Incentive Payment | | | 583,292 | | | 1,166,584 | | | 583,292 | | | 583,292 | | | 583,292 | | | — | | | — | |
| Benefits Continuation | | | 14,643 | | | 21,965 | | | 7,322 | | | — | | | — | | | — | | | — | |
| Accelerated Option Vesting | | | 746,965 | | | 1,712,403 | | | 1,712,403 | | | 1,712,403 | | | 1,712,403 | | | — | | | 746,965 | |
| Accelerated RSU Vesting | | | 1,290,125 | | | 3,564,556 | | | 3,564,556 | | | 3,564,556 | | | 3,564,556 | | | — | | | 1,290,125 | |
| Accelerated PSU Vesting(3) | | | — | | | — | | | — | | | 641,774 | | | — | | | — | | | 641,774 | |
| John A. Way | | | | | | | | | | | | | | | | |||||||
| Base Salary Payment | | | 367,985 | | | 367,985 | | | 367,985 | | | — | | | — | | | — | | | — | |
| Incentive Payment | | | 275,989 | | | 551,978 | | | 551,978 | | | — | | | — | | | — | | | — | |
| Benefits Continuation | | | 15,302 | | | 15,302 | | | 15,302 | | | — | | | — | | | — | | | — | |
| Accelerated Option Vesting | | | 516,771 | | | 1,118,288 | | | 1,118,288 | | | 1,118,288 | | | 1,118,288 | | | — | | | — | |
| Accelerated RSU Vesting | | | 859,768 | | | 2,272,928 | | | 2,272,928 | | | 2,272,928 | | | 2,272,928 | | | — | | | — | |
| Accelerated PSU Vesting(3) | | | — | | | — | | | — | | | 231,020 | | | — | | | — | | | — | |
| Arthur R. Baker III | | | | | | | | | | | | | | | | |||||||
| Base Salary Payment | | | 317,044 | | | 317,044 | | | 317,044 | | | — | | | — | | | — | | | — | |
| Incentive Payment | | | 158,522 | | | 317,044 | | | 317,044 | | | — | | | — | | | — | | | — | |
| Benefits Continuation | | | 5,593 | | | 5,593 | | | 5,593 | | | — | | | — | | | — | | | — | |
| Accelerated Option Vesting | | | 295,341 | | | 733,889 | | | 733,889 | | | 733,889 | | | 733,889 | | | — | | | — | |
| Accelerated RSU Vesting | | | 550,207 | | | 1,532,619 | | | 1,532,619 | | | 1,532,619 | | | 1,532,619 | | | — | | | — | |
| Accelerated PSU Vesting(3) | | | — | | | — | | | — | | | 154,014 | | | — | | | — | | | — | |
| Robert Bodor | | | | | | | | | | | | | | | | |||||||
| Base Salary Payment | | | 338,658 | | | 338,658 | | | 338,658 | | | — | | | — | | | — | | | — | |
| Incentive Payment | | | 203,195 | | | 406,390 | | | 406,390 | | | — | | | — | | | — | | | — | |
| Benefits Continuation | | | 6,181 | | | 6,181 | | | 6,181 | | | — | | | — | | | — | | | — | |
| Accelerated Option Vesting | | | 345,955 | | | 748,851 | | | 748,851 | | | 748,851 | | | 748,851 | | | — | | | — | |
| Accelerated RSU Vesting | | | 577,271 | | | 1,524,796 | | | 1,524,796 | | | 1,524,796 | | | 1,524,796 | | | — | | | — | |
| Accelerated PSU Vesting(3) | | | — | | | — | | | — | | | 154,014 | | | — | | | — | | | — | |
| Bjoern Klaas | | | | | | | | | | | | | | | | |||||||
| Base Salary Payment | | | 324,274 | | | 324,274 | | | 324,274 | | | — | | | — | | | — | | | — | |
| Incentive Payment | | | 162,137 | | | 324,274 | | | 324,274 | | | — | | | — | | | — | | | — | |
| Benefits Continuation | | | — | | | — | | | — | | | — | | | — | | | — | | | — | |
| Accelerated Option Vesting | | | 53,191 | | | 216,135 | | | 216,135 | | | 216,135 | | | 216,135 | | | — | | | — | |
| Accelerated RSU Vesting | | | 146,102 | | | 856,125 | | | 856,125 | | | 856,125 | | | 856,125 | | | — | | | — | |
| Accelerated PSU Vesting(3) | | | — | | | — | | | — | | | 102,676 | | | — | | | — | | | — | |
(1) | The LTIP provides that, in connection with a change in control, we may, among other actions, (i) arrange for the surviving or successor entity to continue, assume or replace outstanding awards under the LTIP, (ii) accelerate the vesting and exercisability of outstanding awards upon the occurrence of the change in control or (iii) cancel outstanding awards in exchange for payment of the amount of consideration that would have been received in the change in control for the number of shares subject to the award, less the aggregate exercise price (if any) of the award. The amounts shown assume acceleration of all outstanding awards under the LTIP in connection with a change in control. |
(2) | Pursuant to agreements between us and each of our named executive officers each such named executive officer is entitled to the payments and benefits summarized above if his or her employment terminates within 90 days prior to a change in control, and if the termination is without cause or for good reason and the executive reasonably demonstrates within 30 days after the change in control that the qualifying termination arose in connection with or in anticipation of the change in control. |
(3) | Upon termination of the executive officer’s employment by us without cause or by the executive for good reason or due to retirement or disability, a pro rata portion (based on the portion of the performance period that elapsed prior to the date of termination) of the number of PSUs that would have been earned at the end of the applicable performance periods if employment had continued will vest on the scheduled vesting date. Because the PSU awards are not accelerated under such circumstances, and because the determination regarding the number of outstanding PSUs to be earned cannot be made until after the applicable performance periods end on December 31, 2021 and 2022, no accelerated values for outstanding PSU awards are included in the table columns relating to retirement, disability and without cause and good reason terminations. |
Annual cash retainer: | | | $50,000 |
| | ||
Annual cash retainer for Chairman: | | | $50,000 |
| | ||
Annual cash retainer for committee chairs: | | | Audit Committee: $20,000 Compensation Committee: $15,000 Nominating and Governance Committee: $10,000 |
| | ||
Annual cash retainer for other committee members: | | | Audit Committee: $8,000 Compensation Committee: $6,000 Nominating and Governance Committee: $4,000 |
| | ||
Annual equity award: | | | $145,000 grant date fair value of restricted stock units or deferred stock units (at the director’s election) which become vested in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting of our shareholders |
| | ||
New director equity award: | | | Restricted stock units with $100,000 grant date fair value, granted on the date the director is first elected to the board |
| | ||
Meeting fees: | | | Generally none, but compensation committee has the discretion to provide for meeting fees if the number of board of directors meetings exceeds eight per year or if the number of meetings of any committee exceeds six per year |
| Name | | | Fees Earned or Paid in Cash ($) | | | Stock Awards ($) | | | Option Awards ($) | | | Total | |
| Archie C. Black | | | 82,750 | | | 140,000 | | | — | | | 222,750 | |
| Sujeet Chand | | | 55,917 | | | 140,000 | | | — | | | 195,917 | |
| Moonhie Chin | | | 48,383 | | | 140,000 | | | — | | | 188,383 | |
| Rainer Gawlick | | | 68,917 | | | 140,000 | | | — | | | 208,917 | |
| John B. Goodman | | | 61,450 | | | 140,000 | | | — | | | 201,450 | |
| Donald G. Krantz | | | 45,917 | | | 140,000 | | | — | | | 185,917 | |
| Sven A. Wehrwein | | | 89,083 | | | 140,000 | | | — | | | 229,083 | |
| Name | | | Number of Shares Underlying Unexercised Options | | | Number of Shares Subject to Unvested DSUs | | | Number of Shares Subject to Unvested RSUs | |
| Archie C. Black | | | — | | | 1,197 | | | — | |
| Sujeet Chand | | | — | | | 1,197 | | | — | |
| Moonhie Chin | | | — | | | 1,197 | | | — | |
| Rainer Gawlick | | | 4,055 | | | 1,197 | | | — | |
| John B. Goodman | | | — | | | 1,197 | | | — | |
| Donald G. Krantz | | | — | | | — | | | 1,197 | |
| Sven A. Wehrwein | | | 6,055 | | | 1,197 | | | — | |
| THE BOARD, UPON RECOMMENDATION OF THE AUDIT COMMITTEE, UNANIMOUSLY RECOMMENDS THAT SHAREHOLDERS VOTE “FOR” THE RATIFICATION OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR FISCAL 2021. | |
| | | Fiscal Year | | ||||
| | | 2020 | | | 2019 | | |
| Audit Fees | | | $1,103,540 | | | $957,043 | |
| Audit-Related Fees | | | 27,500 | | | — | |
| Tax Fees | | | — | | | — | |
| All Other Fees | | | — | | | — | |
| Total | | | $1,131,040 | | | $957,043 | |
| THE BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE “FOR” THE ADVISORY (NONBINDING) RESOLUTION. | |